Relation between bronchial responsiveness to inhaled leukotriene D₄ and markers of leukotriene biosynthesis

P Gyllfors, M Kumlin, S-E Dahlén, F Gaber, P-O Ehrs, B Dahlén

Background: While clinical trials with antileukotrienes have shown overall beneficial effects in asthma, the factors that determine leukotriene dependent asthma are still unclear. A study was undertaken to determine whether or not leukotriene responsiveness in the airways correlates with endogenous leukotriene biosynthesis.

Methods: Bronchial responsiveness to leukotriene (LT) D₄ was assessed as PD₂₀FEV₁ in 20 subjects with mild asthma and 10 healthy controls, and compared with bronchial responsiveness to methacholine and two global measures of leukotriene production—urinary LTE₄ and ex vivo production of LTB₄ in whole blood.

Results: In patients with asthma the bronchoconstrictor activity of LTD₄ was about 1300 times greater than methacholine (geometric mean PD₂₀ 0.69 nmol vs 887 nmol). Those who were most responsive to LTD₄ were relatively less responsive to methacholine (p<0.01). There was, however, no correlation between bronchial responsiveness to LTD₄ and urinary LTE₄ or blood ex vivo LTB₄ levels in asthmatic subjects or healthy controls. Subjects with asthma treated with inhaled corticosteroids produced higher levels of LTB₄ (p<0.05).

Conclusions: General measures of leukotriene production cannot predict bronchial responsiveness to LTD₄. The unique bronchoconstrictive potency of LTD₄ on human airways may relate to the locally regulated expression of the cysteinyll LT₁ receptor.

The leukotrienes (LT) and, in particular, the cysteinyll leukotrienes (CysLTs; LTC₄, LTD₄ and LTE₄) mediate central components of asthmatic airway inflammation such as bronchospasm, mucus production, eosinophil recruitment, and vascular reactions leading to tissue oedema. Over the past decade antileukotrienes—that is, drugs which block the formation or actions of leukotrienes—have been introduced as new treatments for asthma. Antileukotrienes therefore have a completely different mode of action from that of other asthma medications.

The further clinical use of antileukotriene drugs is, however, hampered by a lack of understanding of which patients benefit from this treatment. There is a distribution of clinical responsiveness to antileukotriene drugs that suggests the presence of responders and non-responders. Attempts to correlate the treatment response with genetic polymorphism in 5-lipoxygenase (the first enzyme in the leukotriene pathway) or leukotriene C₄ synthase (the enzyme initiating production of CysLTs) have produced conflicting results. So far, no major genetic determinant of leukotriene dependent asthma has been identified.

Another strategy in the quest to define responsiveness to antileukotriene drugs has been to define more precisely the phenotypic characteristics of such patients. The focus has been on the possibility that the propensity to generate leukotrienes during asthmatic inflammation is a marker of leukotriene dependent asthma. This hypothesis has received some support from the observations that subjects with aspirin intolerant asthma (AIA) respond well to antileukotriene treatment and have a high basal production of leukotrienes measured as urinary LTE₄ (U-LTE₄). It has also been claimed that the degree of ex vivo release of CysLTs from blood leucocytes is correlated directly with the clinical response to the leukotriene receptor antagonist pranlukast. However, in patients with AIA there was no correlation between U-LTE₄ and the treatment response to the leukotriene antagonist montelukast.

While it is uncertain whether the production of leukotrienes correlates with the beneficial effect of antileukotrienes, the responsiveness to leukotrienes in the airways has not been taken into account. It is not known if increased bronchial responsiveness to leukotrienes is an indicator of a predominant leukotriene component in asthmatic inflammation. We have therefore embarked on a series of studies of factors that determine leukotriene responsiveness in the airways. The aim of the first investigation in this project was to assess whether or not the responsiveness of an individual to inhaled LTD₄ is related to the general propensity to synthesise leukotrienes. As CysLTs cause bronchoconstriction and many other biological effects by activation of the G protein coupled CysLT₁ receptor, it was hypothesised that there might be a relation between the endogenous level of agonist (CysLTs) and the airway responsiveness to inhaled LTD₄. It is common for agonist levels to influence the degree of receptor expression. For this study, two different global measures of leukotriene production—U-LTE₄ and blood ex vivo LTB₄ generation—were assessed. LTE₄ is the end product of the CysLTs excreted into the urine and its level is a reflection of whole body biosynthesis of CysLTs. As circulating levels of leukotrienes in the blood are very low and far below the detection limit of reliable assays, standardised ex vivo stimulation of whole blood with secretagogues such as a calcium ionophore has been necessary.

Abbreviations: CysLT, cysteinyll leukotriene; FEV₁, forced expiratory volume in 1 second; Feno, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; MCh, methacholine; PD₁₀, PD₁₅, PD₂₀, provocative dose causing a 10%, 15% and 20% decrease in FEV₁
Markers of leukotriene biosynthesis in asthma

introduced as an indirect method of assessing the biosynthetic capacity of blood cells for leukotriene production. In this setting LTB_4 is the main leukotriene formed, and its synthesis is thought to reflect the degree of 5-lipoxygenase activity.

This cross sectional study of 20 subjects with asthma and 10 healthy controls therefore tested whether bronchial responsiveness to LTD_4, expressed as the PD_{20} value, was correlated with leukotriene production measured as U-LTE_4 and blood ex vivo production of LTB_4. Bronchial responsiveness to LTD_4 was also compared with responsiveness to methacholine (MCh), selected as a general marker of airway responsiveness, and with the fraction of expired nitric oxide (FeNO) as a surrogate marker of airway inflammation, both being common asthma outcome variables in treatment studies. Although descriptive data on LTD_4 responsiveness are available in the literature, there is almost no mechanistic information about factors that determine leukotriene responsiveness in humans. 

**METHODS**

**Subjects**

Twenty subjects with intermittent to mild asthma according to GINA criteria and documented airway hyperresponsiveness to MCh and 10 healthy individuals were included in the study. Subjects with asthma were recruited from a general practitioner’s clinic and the healthy volunteers through advertisements. All subjects were never smokers or non-smokers for the last 2 years with a smoking history of less than 5 pack years who had not had a respiratory tract infection during the 4 weeks before screening. Atopic subjects were skin prick test negative to 10 allergens of the panel. To be included in the study, subjects with asthma had to be GINA criteria 18 and documented airway hyperresponsiveness to LTD_4. Ten of the asthmatic subjects used a stable dose of inhaled corticosteroids (ICS) and short acting _β_2 agonists as their sole medication (table 1).

FeNO, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; SABA, short acting _β_2 agonist; SPT, skin prick test; FeNO, fraction of expired nitric oxide; QoL, quality of life.

**Lung function data at baseline (visit 1).**

**Study design**

The screening visit included subject characterisation with documentation of history, a MCh challenge, and a skin prick test. Three further visits were scheduled 2 weeks apart, and the subjects always reported to the clinic at the same time in the morning. At visit 1 Feso was measured according to the ATS/ERS standard, 19 dynamic spirometric tests were performed, blood samples were collected for analysis of whole blood ex vivo LTD_4 production, and urinary samples were collected for analysis of baseline U-LTE_4 concentrations. In the subjects with asthma, quality of life was measured using the Asthma Quality of Life Questionnaire (AQLQ) devised by Juniper et al. 20 The patients were asked to indicate the extent to which their quality of life was limited on a 7-point scale where 1 indicates maximal impairment and 7 no impairment at all. At visit 2, blood and urine samples were collected and spirometric tests performed as the subjects underwent a bronchoscopic examination as part of a separate ongoing mechanistic investigation of the leukotriene pathway in the lung. At visit 3, inhalation challenge with LTD_4 was performed in addition to blood and urine sampling. Short acting _β_2 agonists were withheld for at least 6 hours before visits except for visit 2.

**Inhalation challenge**

Pulmonary function was measured as FEV_1 on a spirometer (Vitalograph MDI Compact; Förbandsmaterial, Stockholm, Sweden) and the baseline defined as the best of three recordings. All bronchoprovocation tests were performed using a dosimeter controlled jet nebuliser (Spira Elektro 2; Intramedic, Bålst, Sweden). Challenges always began with inhalation of the respective diluent. Provided FEV_1 did not change by more than 10%, incremental doses of the provocative agent were administered until FEV_1 had fallen by at least 20% from post-diluent baseline. For LTD_4 bronchoprovocation tests, approximately half-log increments in the cumulative dose (3, 10, 30 pmol) were inhaled every 10 minutes (dose range 3–335 780 pmol). This was achieved by using six solutions of good manufacturing practice (GMP) grade LTD_4 (sealed colour coded vials each containing 1 ml of solution; concentrations increasing by tenfold from 4.2×10^{-9} M to 4.2×10^{-3} M; 4:1 solvent water:ethanol; Cascade Biochemicals; Reading, UK) and a varying number of breaths (2–7) from each solution. Spirometric tests were performed 5 and 10 minutes after each dose and the peak fall used for calculation of PD_{20}. Airway responsiveness to MCh was assessed with a similar protocol but with dose increments every 3 minutes and single FEV_1 measurements.
Three concentrations (6.24, 50, 400 mM prepared at Norrlands University Hospital Pharmacy) were used to create increasing doses (range 89–45282 nmol).

Collection of urine samples and analysis of urinary LTE4
Urine was collected on arrival on each of the three study days, two samples at visit 1 with 1 hour in between and one sample at visits 2 and 3. The total volumes of the urine samples were measured, aliquoted, immediately frozen without preservatives, and stored at −20°C until analysis. The concentration of LTE4 was determined using a previously validated enzyme immunoassay method with data expressed in relation to creatinine excretion determined colorometrically.21 The rabbit polyclonal CysLT antiserum used in the present study cross reacted with LTE4 (67%), LTC4 (100%), and LTD4 (100%). Acetylcholine esterase linked LTE4 was used as tracer and unlabelled LTE4 as standard. Baseline U-LTE4 refers to the mean value of the four baseline samples.

Ex vivo ionophore induced formation of LTB4 in whole blood
Blood samples were obtained by venepuncture into heparinised vaccutainer tubes upon arrival at visits 1, 2 and 3. Ex vivo stimulation of freshly drawn peripheral whole blood was performed with a modified version of previously described protocols.16–22 The blood was kept at room temperature for 1 hour before incubation to minimise fluctuations in values due to decreased capacity for leukotriene formation within the first hour of blood collection.16 The calcium ionophore ionomycin was dissolved in 95% ethanol to a stock concentration of 10 mM. The stock solution and vehicle (95% ethanol) were diluted 10 times with autologous plasma. Aliquots of blood (1 ml) were preincubated at 37°C for 2 minutes, followed by addition of vehicle or ionomycin in 50 μl autologous plasma. The final concentration of ionomycin was 50 μM. Incubations were continued for 15 minutes at 37°C and interrupted on ice. Plasma was obtained by centrifugation at 714g for 5 minutes at 4°C and stored at −70°C until assayed for LTB4 by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI, USA). Data were expressed in relation to the white blood cell (WBC) count on each blood collection day. The mean values of the three visit days were used for comparisons between groups, whereas correlation with PD20LTD4 was tested for values obtained on the day of the bronchoprovocation (visit 3).

Statistical analysis
The provocative doses causing falls of 10%, 15% and 20% in FEV1 (PD10, PD15, PD20) were derived by linear interpolation from the respective log cumulated dose-response curves. Calculations of geometric mean values were performed on log transformed raw data. Urinary LTE4 and ex vivo LTB4 concentrations are expressed as median values with ranges. Correlations between bronchial challenges were performed with Pearson product moment correlation and all others with Spearman rank order correlation. The Mann-Whitney rank sum test was used for comparison between groups and Kruskal-Wallis one way analysis of variance on ranks was used to assess variability in values of ex vivo LTB4 and U-LTE4 at baseline. Differences were considered significant if p < 0.05.

RESULTS
Bronchial responsiveness to LTD4 and MCh
The dose-response relations for inhaled LTD4 and MCh in all individuals are shown in fig 1A–C, and group mean data for different measures of responsiveness are given in table 2. All subjects with asthma produced PD20 values for LTD4 and MCh with no significant difference in responsiveness between the group taking ICS and the group that did not

Figure 1  Individual dose-response curves for LTD4 (left) and methacholine (right) in (A) healthy subjects, (B) non-ICS treated asthmatics, and (C) ICS treated asthmatic subjects. (D) Comparison of airway responsiveness to inhaled LTD4 and methacholine indicated by the respective log PD20 values in the asthmatic subjects (r = 0.73, p < 0.001, Pearson product moment correlation). ICS, inhaled corticosteroids.
The geometric mean (range) PD_{20}LTD4 and PD_{20}MCh for all subjects with asthma (n = 20) was 0.69 (0.062–37.05) nmol and 887 (89–37 188) nmol, respectively. Thus, on a molar basis, LTD4 was over a 1000 times more potent than MCh (PD_{20} ratio 877/0.69 = 1285; fig 1B and C). The very similar dose ratios between LTD4 and MCh were also obtained if PD_{15} or PD_{10} values were compared in the subjects with asthma (table 2). The geometric mean (range) PD_{20}MCh was 0.74 (0.06–6.43) and 0.65 (0.15–37.05) in the asthma (no ICS) and asthma (ICS) groups, respectively.

In the healthy subjects the fall in FEV1 in response to the highest cumulative dose of MCh (45 282 nmol) was less than 15% for eight of the 10 subjects (fig 1A). In contrast, LTD4 produced a PD_{20} in seven of the healthy subjects and PD_{15} could be determined for nine (fig 1A and table 2). Compared with the asthmatic subjects, the healthy subjects were about 40 times less sensitive to either LTD4 or MCh when PD_{15} values for LTD4 or PD_{10} values for both compounds were compared (table 2). As in the asthmatic subjects, LTD4 was more than 1000 times more potent than MCh when PD_{10} values for LTD4 and MCh were compared in the seven healthy individuals who responded to MCh (fig 1A and table 2).

There was no correlation between the responsiveness to inhaled LTD4 and FeNO in subjects with asthma or in healthy individuals at the PD_{15} level (data not shown).

**Blood ex vivo LTB4 production and urinary excretion of LTE4**

Urinary LTE4 excretion and ex vivo LTB4 production were consistent within each study group with no significant differences between the three visit days (table 3), nor were there differences in baseline U-LTE4 excretion between the three study groups (p > 0.05, table 3). However, asthmatic subjects taking ICS had higher ex vivo LTB4 production than those with asthma not taking ICS (median (range) 10.7 (4.3–21.5) v 7.0 (2.5–18.1) ng/10^6 WBC, p < 0.05). There was no correlation between ex vivo LTB4 production and U-LTE4 in either the asthmatic subjects (p > 0.05) or in the healthy individuals (p > 0.05, data not shown).

Furthermore, there was no correlation between airway responsiveness to LTD4 and ex vivo LTD4 generation on the day of provocation in subjects with asthma (n = 20, r = 0.36, p = 0.12) or in the healthy individuals (n = 7, r = −0.12, p = 0.80; fig 3A). Likewise, there was no correlation between responsiveness to inhaled LTD4 and baseline U-LTE4 concentrations in subjects with asthma (n = 20, r = −0.22, p = 0.36) or in healthy individuals (n = 7, r = −0.17, p = 0.71; fig 3B).

**DISCUSSION**

No relationship was found between two global measures of leukotriene biosynthesis and bronchial responsiveness to inhaled LTD4. Although baseline data (including asthma specific quality of life) indicated that the subjects with asthma had relatively similar disease severity, their responsiveness to LTD4 varied by almost 1000 times (PD_{20} from 60 pmol to 40 nmol (30 ng to 20 µg). There was also no relation between LTD4PD_{20} and exhaled NO, although the latter displayed the expected difference between healthy subjects and asthmatics (table 1).

**Table 2** Geometric mean (range) bronchial responsiveness data

<table>
<thead>
<tr>
<th></th>
<th>Healthy subjects (n = 10)</th>
<th>Asthma (no ICS) (n = 10)</th>
<th>Asthma (ICS) (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD_{20}LTD4 (nmol)</td>
<td>14.1 (6.47–40.37)</td>
<td>0.74 (0.06–6.43)</td>
<td>0.65 (0.15–37.05)</td>
</tr>
<tr>
<td>PD_{20}MCh (nmol)</td>
<td>nd</td>
<td>913 (89–25457)</td>
<td>862 (89–37 188)</td>
</tr>
<tr>
<td>Ratio PD_{20}MCh/PD_{20}LTD4</td>
<td>nd</td>
<td>1234 (174–17557)</td>
<td>1326 (206–5825)</td>
</tr>
<tr>
<td>PD_{15}LTD4 (nmol)</td>
<td>16.50 (2.9–192.1)</td>
<td>0.41 (0.04–5.17)</td>
<td>0.41 (0.07–12.27)</td>
</tr>
<tr>
<td>Ratio PD_{15}LTD4 healthy/v asthma</td>
<td>40.2 (16.5/0.41)</td>
<td>659 (89–19316)</td>
<td>582 (89–27298)</td>
</tr>
<tr>
<td>PD_{15}MCh (nmol)</td>
<td>nd</td>
<td>1607 (575–30181)</td>
<td>1420 (240–5982)</td>
</tr>
<tr>
<td>Ratio PD_{15}MCh/PD_{15}LTD4</td>
<td>nd</td>
<td>0.18 (0.01–1.25)</td>
<td>0.22 (0.04–3.00)</td>
</tr>
<tr>
<td>PD_{10}LTD4 (nmol)</td>
<td>35.7 (7.14/0.20)</td>
<td>330 (89–2430)</td>
<td>270 (89–9819)</td>
</tr>
<tr>
<td>Ratio PD_{10}LTD4 healthy/v asthma</td>
<td>43.2 (12974/300)</td>
<td>43.2 (12974/300)</td>
<td>270 (89–9819)</td>
</tr>
<tr>
<td>PD_{10}MCh (nmol)</td>
<td>12.974 (3830–47351)</td>
<td>1282 (321–7399)</td>
<td>1282 (321–7399)</td>
</tr>
<tr>
<td>Ratio PD_{10}MCh/PD_{10}LTD4</td>
<td>1827 (321–7399)</td>
<td>1852 (832–18743)</td>
<td>1282 (321–7399)</td>
</tr>
</tbody>
</table>

MCh, methacholine; PD_{10}, PD_{15}, PD_{20}, provocative dose causing 10%, 15% and 20% decrease in FEV1; nd, could not be determined.

Non-ICS treated asthmatics
ICS treated asthmatics

Figure 2 Relation between airway responsiveness to methacholine (PD_{20}) and the relative potency of LTD4 compared with methacholine (dose ratio of MCh/PD_{20} to LTD4/PD_{20}). The linear relation between the two variables (r = 0.6, p < 0.01, Pearson product moment correlation) indicates that the asthmatic subjects who were the most responsive to methacholine had the least relative airway responsiveness to LTD4.
In the search for factors that determine leukotriene responsiveness in the airways, the effects of inhaled LTD₄ were examined in one of the largest bronchoprovocation studies (n = 30) completed with this agent. Subjects with mild asthma, half of whom were receiving treatment with ICS, were chosen because they represent the vast majority (approximately 70%) of all asthma patients. Thus, in subjects with asthma, LTD₄ was (on a molar basis) more than 1000 (approximately 70%) of all asthma patients. Thus, in subjects with more severe airway inflammation and greater exposure to endogenous LTD₄ in their inflamed airways.

Our findings support the hypothesis that subjects with asthma and a high degree of airway reactivity have developed tachyphylaxis to LTD₄ presumably because of high exposure to endogenous LTD₄ in their inflamed airways. Another explanation for the findings in fig 2 might be that LTD₄ in subjects with more inflamed airways stimulates the release of bronchoprotective factors such as nitric oxide or prostaglandin E₂. The conclusion that LTD₄ has a very specific mode of action on the airways is also supported by the current observation that there was no relation between LTD₄PD₂₀ and exhaled NO, whereas MCh responsiveness has been reported to be correlated with exhaled NO levels.

It was confirmed that LTD₄ is also a potent bronchoconstrictor in subjects without asthma. Interestingly, a PD₂₀ value for LTD₄ could be obtained in seven out of 10 healthy individuals whereas only two subjects had a fall in FEV₁ of more than 12% after inhalation of the highest dose of MCh used in this protocol. The latter observation is in line with the established plateau to MCh in healthy subjects. The less apparent plateau to LTD₄ might relate to its longer duration of action in airway smooth muscle compared with agonists such as histamine or MCh. Bel et al found that the maximal airway narrowing to LTD₄ was much greater than that produced by MCh. In agreement with these fundamental differences in action on the airways, the potency ratio between LTD₄ and MCh (1827) could only be determined on a PD₁₀ level in the healthy controls. However, when LTD₄ responsiveness was compared for the groups, the healthy controls were about 40 times less responsive than the subjects with asthma. Thus, although MCh and LTD₄ are both direct bronchoconstrictors, the difference in relative potency for the two classes of bronchoconstrictors in asthmatics with varying degree of hyperresponsiveness indicates that each bronchoconstrictor has unique effects on the airways in asthma.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Median (range) leukotriene levels on the three visit days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1</td>
<td>Visit 2</td>
</tr>
<tr>
<td>Blood ex vivo LTE₄ (ng/10⁶ WBC)</td>
<td></td>
</tr>
<tr>
<td>Asthma, not ICS</td>
<td>6.32 (3.31–13.56)</td>
</tr>
<tr>
<td>Asthma ICS</td>
<td>8.04 (4.34–21.55)</td>
</tr>
<tr>
<td>Baseline urinary LTE₄ (ng/mmol creatinine)</td>
<td></td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>22.64 (16.34–48.15)</td>
</tr>
<tr>
<td>Asthma, not ICS</td>
<td>24.41 (16.85–51.96)</td>
</tr>
<tr>
<td>Asthma ICS</td>
<td>22.92 (11.69–59.35)</td>
</tr>
</tbody>
</table>

WBC, white blood cells; ICS, inhaled corticosteroids. Within each study group there was no significant difference between the three study days (ANOVA) for any of the variables.

Figure 3 No relation was seen between airway responsiveness to inhaled LTD₄ and two general markers of leukotriene production in subjects with asthma or in healthy individuals (Spearman rank order correlation): (A) blood ex vivo LTE₄ production; (B) baseline U-LTE₄ concentration.

www.thoraxjnl.com
Markers of leukotriene biosynthesis in asthma

707

asthma and healthy controls. Measurements of ex vivo LTB4 formation in whole blood also failed to establish a relation between this measure and airway responsiveness to LTD4 for asthmatics or healthy controls. Taken together, the study therefore refuted the hypothesis that there is a relation between airway responsiveness to LTD4 and the global propensity of individuals to generate leukotrienes measured either as U-LTE4 or blood ex vivo LTB4 production. It is likely that the expression of CySLT1 receptors in the airways is the primary determinant of responsiveness to inhaled LTD4. CySLT1 receptor expression and hence responsiveness to the inhaled agonist may, however, still be regulated by the local biosynthesis of leukotrienes in the airways measured, for example, in sputum, bronchoalveolar lavage (BAL) fluid or cells recovered from BAL fluid. Mechanistic studies to address these possibilities are ongoing.

Interestingly, we found that asthmatic patients who were receiving ICS produced somewhat higher levels of LTB4 whereas their urinary excretion of LTE4 was the same as in asthmatic patients not treated with ICS. The finding with LTB4 is new and, together with the confirmatory data on urinary LTE4, adds to the knowledge that ICS have complex effects on the leukotriene pathway with no or minimal effects on leukotriene biosynthesis generally observed in vivo. The increased levels of steroid treatment might relate to the prolonged function of the 5-lipoxygenase and TxA2 expression in cells may be upregulated by ICS. As there was no correlation between ex vivo generation of LTB4 and U-LTE4 for the individual subjects, the study also confirms the hypothesis that these two measures represent two different ways to assess the leukotriene pathway.

In conclusion, the lack of relationship between global markers of biosynthesis of leukotrienes and responsiveness to LTD4 is noteworthy in view of the limited usefulness of these markers to predict the response to anti-leukotriene drugs. Since subjects with asthma in the current study displayed a wide three log order of magnitude variability in responsiveness to inhaled LTD4, variability in the sensitivity of the target tissue to the effects of CySLT may perhaps be a more decisive determinant of the treatment response to anti-leukotriene drugs. We therefore propose that future trials aimed at the establishment of responders to anti-leukotriene treatment should include PD20FEV1 for LTD4. We hypothesise that such a direct measure of airway responsiveness may be more predictive than the markers of biosynthesis currently used. Alternatively, a composite measurement integrating both airway responsiveness and an appropriate end point for leukotriene biosynthesis may be required to define leukotriene dependent asthma.

ACKNOWLEDGEMENTS

The authors acknowledge the assistance from Ingrid Delin, Margaret Andersson, Margitha Dahl, Gunnell de Forest, Helène Blomqvist, and Elisabeth Henriksson.

Authors' affiliations

P Gyllfors, Division of Respiratory Medicine, Department of Medicine at Karolinska University Hospital Solna, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden
M Kumin, S-E Dahlén, F Gaber, P-O Ehrs, Division of Physiology, The National Institute of Environmental Medicine, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden
P-O Ehrs, Family Medicine Stockholm, Department of Clinical Science, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden
B Dahlén, Division of Respiratory Medicine, Department of Medicine at Karolinska University Hospital Huddinge, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden

Supported by Karolinska Institutet, Centre for Allergy Research and the Stockholm County Council (ALF), and the following Swedish foundations: Heart Lung Foundation, Association Against Asthma and Allergy, Consul Bergh’s Foundation, Medical Research Council (projects 14X-9071 and 74X-15067), and the Foundation for Health Care Sciences and Allergy Research (Vårdal). This study received no support from the pharmaceutical industry.

Competing interests: none declared

REFERENCES

Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma. Thorax 2002; 57: 575–80.


---

Roflumilast as a treatment for COPD


Chronic inflammation is the key pathophysiological mechanism in the development of COPD and there is increasing interest in the potential role of novel anti-inflammatory treatments. This phase III multicentre double blind study focuses on roflumilast, an oral phosphodiesterase 4 inhibitor.

1411 patients with stable moderate to severe COPD were randomised to receive placebo, roflumilast 250 μg once daily, or roflumilast 500 μg once daily for 24 weeks. The primary outcome measures were post-bronchodilator forced expiratory volume in 1 second (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score. Secondary outcome measures included the number of COPD exacerbations. The results showed a mean (SD) improvement in FEV1 of 74 (18) ml with roflumilast 250 μg and 97 (18) ml with roflumilast 500 μg compared with placebo at 24 weeks (p<0.0001). There were no significant differences in the SGRQ scores between the roflumilast and placebo groups. The mean number of exacerbations was reduced by 34% in the roflumilast 500 μg group compared with the placebo group, primarily due to a reduction in mild exacerbations (42%, p = 0.004). Adverse effects were predominantly gastrointestinal in nature and self-limiting.

This study provides encouraging initial data to support the use of roflumilast in patients with COPD. Further studies are needed to confirm that these results are sustained beyond 24 weeks and to assess further the effects on health-related quality of life.

E Nash
Specialist Registrar, Frenchay Hospital, Bristol, UK; ednash2000@hotmail.com
Roflumilast as a treatment for COPD

E Nash

Thorax 2005 60: 908
doi: 10.1136/thx.2005.la0175